JOURNAL OF THORACIC ONCOLOGY Journal
Overview
publication venue for
- A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors 2024
- Patient Preferences for EGFR Exon 20 Insertion-Targeted Therapies in NSCLC: A Multi-Dimensional Thresholding Analysis 2024
- Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. 19:941-953. 2024
- Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants 2023
- Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins 2023
- Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). 18:1031-1041. 2023
- Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI) 2023
- Developing of EGFR resistant mutations to Tyrosine Kinase Inhibitors (TKI) in Non-Small Cell Lung Cancer (NSCLC) 2022
- PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) 2022
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. 17:309-323. 2022
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC. 16:1909-1924. 2021
- Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease 2021
- Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150 2021
- Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes From EXCLAIM Extension Cohort 2021
- Mobocertinib in EGFR Exon 20 InsertionePositive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy 2021
- Mobocertinib in Platinum-Pretreated EGFR Exon 20 Insertion+ Metastatic NSCLC Patients With/Without Prior Anti-PD(L)-1 Therapy 2021
- Crizotinib in Patients With MET-Amplified NSCLC. 16:1017-1029. 2021
- Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. 16:653-664. 2021
- A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation 2021
- Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations 2021
- Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients 2021
- CRESTONE e Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions e A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210) 2021
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. 15:1351-1360. 2020
- IMpower131: Final OS Results of Carboplatin plus Nab-Paclitaxel +/- Atezolizumab in Advanced Squamous NSCLC 2019
- Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study 2019
- New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting 2019
- Phase 3, Randomized, Double-Blind Trial of First-Line Pembrolizumab With or Without Lenvatinib in Metastatic NSCLC: LEAP-007 2019
- An Open-Label, Non-Randomized, Biomarker Study of Concordance in Non-Invasive and Tissue Tests for T790M Detection in NSCLC 2018
- Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC 2018
- Outcomes of Patients < 70 or >= 70 Years of Age in PACIFIC 2018
- Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC 2018
- Primary PFS and safety analyses of a randomized phase III study of carboplatin plus paclitaxel plus /- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) 2018
- Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer 2018
- EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. 13:228-236. 2018
- Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC 2017
- Plasma CfDNA next Generation Sequencing in Non-Small Cell Lung Cancer: Clinical Outcomes and Comparison to Tissue 2017
- Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study CALGB 30607 (Alliance). 12:843-849. 2017
- A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma 2017
- A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC 2017
- EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE 2017
- Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study 2017
- First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program 2017
- Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy 2017
- Neratinib Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study 2017
- Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer 2017
- Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK plus NSCLC 2017
- Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment 2016
- ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2 2016
- Evaluation of Novel Blood-Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B-F1RST) 2016
- First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program 2016
- Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review. 11:E135-E139. 2016
- Impact of Race on Treatment and Survival among US Veterans with Early-Stage Lung Cancer. 11:1672-1681. 2016
- Clinicopathologic Features of Advanced Squamous NSCLC 2016
- The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. 11:808-818. 2016
- Activity of Rociletinib in EGFR Mutant NSCLC Patients with a History of CNS Involvement 2015
- Intracranial Efficacy of First-Line Crizotinib vs. Chemotherapy in ALK-Positive NSCLC 2015
- Updated Efficacy/Safety Data From the Phase 2 NP28761 Study of Alectinib in ALK plus NSCLC 2015
- Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer. 10:353-359. 2015
- Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of "Master Protocols" in Lung Cancer. 9:1443-1448. 2014
- Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III-IV Lung Cancer. 9:1264-1271. 2014
- CALGB 30704 (Alliance) A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 9:214-221. 2014
- Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer. 9:83-90. 2014
- RET Rearrangements in Lung Adenocarcinoma and Radiation. 9:118-120. 2014
- Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC Beyond Traditional Treatment Approaches. 8:587-598. 2013
- A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non-Small-Cell Lung Cancer. 8:443-451. 2013
- Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed "Sensitive" Small Cell Lung Cancer. 7:751-754. 2012
- Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer. 7:137-142. 2012
- A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age >= 70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer. 6:1569-1577. 2011
- CORRELATION OF TIMING AND CLINICAL BENEFIT FROM TREATMENT WITH PEMETREXED IN METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) 2011
- Maintenance Therapy in Advanced Non-small Cell Lung Cancer Current Status and Future Implications 2011
- Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. 5:1977-1985. 2010
- Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer. 5:1963-1969. 2010
- A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer. 5:993-1000. 2010
- A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. 5:852-861. 2010
- Safety and Efficacy of Combining Sunitinib with Bevacizumab plus Paclitaxel/Carboplatin in Non-small Cell Lung Cancer. 5:354-360. 2010
- Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer. 5:110-116. 2010
- Fibroblastic Growth Factor Pathway 2009
- A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer The Cleveland Clinic Experience. 4:976-982. 2009
- Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer. 4:983-987. 2009
- Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials. 4:869-874. 2009
- Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy 2009
- Late Complications of High-Dose (>= 66 GY) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer. 4:74-79. 2009
- Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin and Paclitaxel in Unresectable Stage IIIA/B Non-small Cell Lung Cancer. 3:1279-1285. 2008
- Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-in Time Results of a Phase II Trial. 3:1308-1316. 2008
- Randomized phase III trial comparing single-agent paclitaxel poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. 3:728-734. 2008
- Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. 3:623-630. 2008
- Summary statement - Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference assessing opportunities for combination therapy. 3:S107-S112. 2008
- The current status and evolving role of sunitinib in non-small cell lung cancer. 3:S119-S123. 2008
- Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. 3:521-526. 2008
- Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. 3:250-257. 2008
- Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer - Cancer and Leukemia Group B study 39901. 3:158-162. 2008
- The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. 3:145-151. 2008
- Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. 3:37-45. 2008
- Beliefs among physicians in the diagnostic and therapeutic approach to non-small cell lung cancer. 2:819-826. 2007
- Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: A meta-analysis. 2:845-853. 2007
- Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group study 9718. 2:440-444. 2007
Research
category
- ONCOLOGY Web of Science Category
- RESPIRATORY SYSTEM Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 1556-0864
Electronic International Standard Serial Number (EISSN)
- 1556-1380
Other
journal abbreviation
- J THORAC ONCOL